Quick Answer
Vaxcyte, Inc. reported Stockholders Equity of $2.69 billion for fiscal year 2025.
Vaxcyte, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $2.69B | -18.8% |
| 2024 | $3.31B | +166.5% |
| 2023 | $1.24B | +30.1% |
| 2022 | $953.61M | +235.8% |
| 2021 | $284.02M | -17.9% |
| 2020 | $345.84M | +425.1% |
| 2019 | -$106.37M | -84.3% |
| 2018 | -$57.73M | -98.2% |
| 2017 | -$29.13M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.89B | -15.4% | -5.8% |
| June 30, 2025 | $3.07B | +54.6% | -4.0% |
| March 31, 2025 | $3.20B | +61.3% | -3.2% |
| December 31, 2024 | $3.31B | +166.5% | -3.3% |
| September 30, 2024 | $3.42B | +143.6% | +72.1% |
| June 30, 2024 | $1.99B | +38.6% | +0.1% |
| March 31, 2024 | $1.98B | +110.0% | +59.9% |
| December 31, 2023 | $1.24B | +30.1% | -11.6% |
- Vaxcyte, Inc. showed a decrease of -18.8% in Stockholders Equity compared to the prior fiscal year.
- Over the 2017–2025 period, Vaxcyte, Inc.’s stockholders equity has grown by 9319.1% (from -$29.13 million to $2.69 billion).
- The most recent figure is from Vaxcyte, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: